secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066355
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx Q1 net loss $35.9M, cash $204.1M; avexitide Phase 3 underway
-------------------------------------------------------------------

- Q1 net loss $35.9M ($0.42/share), down from $118.8M ($1.75/share) YoY on lower R&D and SG&A costs.
- Cash, equivalents, and marketable securities $204.1M; cash runway expected through end of 2026.
- Phase 3 LUCIDITY trial of avexitide in PBH dosed first patient; enrollment complete 2025, topline data H1 2026.
- Phase 1 LUMINA trial of AMX0114 (ASO for ALS) dosed first patient; early cohort data expected in 2025.
- Closed $65.5M public offering of 19.7M shares in Jan 2025; Phase 2b ORION (PSP) data expected Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017025066355/0000950170-25-066355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017025066355/amlx-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer